Northwest Biotherapeutics, Inc.
NWBO
$0.19
-$0.01-4.43%
OTC PK
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -26.49% | 236.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -26.49% | 236.00% | |||
| Cost of Revenue | -12.53% | -25.45% | |||
| Gross Profit | 10.61% | 32.66% | |||
| SG&A Expenses | -24.19% | 21.95% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -19.62% | -2.37% | |||
| Operating Income | 19.28% | 5.70% | |||
| Income Before Tax | -460.63% | 103.17% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -321.11% | 105.17% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -321.11% | 105.17% | |||
| EBIT | 19.28% | 5.70% | |||
| EBITDA | 20.72% | 7.88% | |||
| EPS Basic | -362.50% | 104.40% | |||
| Normalized Basic EPS | 66.67% | 32.58% | |||
| EPS Diluted | -200.00% | 96.50% | |||
| Normalized Diluted EPS | 66.67% | 32.58% | |||
| Average Basic Shares Outstanding | 3.22% | 2.90% | |||
| Average Diluted Shares Outstanding | 3.22% | 2.90% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||